{"id":147,"date":"2020-07-21T16:42:36","date_gmt":"2020-07-21T14:42:36","guid":{"rendered":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/?page_id=147"},"modified":"2026-07-16T11:31:43","modified_gmt":"2026-07-16T09:31:43","slug":"axe-thor","status":"publish","type":"page","link":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/","title":{"rendered":"Axe Thor"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_custom_heading text=\u00a0\u00bbTarget in Hematology and Oncology Research\u00a0\u00bb font_container=\u00a0\u00bbtag:h2|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb755&Prime;][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb349&Prime; alignment=\u00a0\u00bbcenter\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb1111&Prime;][\/vc_column][\/vc_row][vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1595343295102{margin-right: 20px !important;}\u00a0\u00bb][vc_column_text]<em>Canc\u00e9rologie p\u00e9diatrique, canc\u00e9rologie adulte (oncologie m\u00e9dicale, h\u00e9matologie oncologie, cancer et rein), registre des cancers<br \/>\n<\/em>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=\u00a0\u00bb162&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_accordion style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb12&Prime; no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbVue d&rsquo;ensemble\u00a0\u00bb tab_id=\u00a0\u00bb1614697670792-e384d485-408a\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb.vc_custom_1595343317315{padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #bd3937 !important;}\u00a0\u00bb]\n<ul style=\"color: #ffffff;\">\n<li><span style=\"color: #ffffff;\">Immunosurveillance, immunoth\u00e9rapie<\/span><\/li>\n<li><span style=\"color: #ffffff;\">M\u00e9canismes de r\u00e9sistance aux drogues<\/span><\/li>\n<li><span style=\"color: #ffffff;\">Cellule souche h\u00e9matopo\u00ef\u00e9tique maligne : quiescence et persistance<\/span><\/li>\n<li><span style=\"color: #ffffff;\">Cohortes et parcours de soin en oncologie et h\u00e9matologie<\/span><\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-handshake-o\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1595343447359{margin-bottom: 0px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#bd3937&Prime;][vc_column_text]\n<p style=\"text-align: center;\"><span style=\"color: #bd3937;\"><strong>Collaborations<\/strong><\/span><\/p>\n<p style=\"text-align: center;\">Plateforme INCA biologie mol\u00e9culaire<br \/>\nU1082<br \/>\nCNRS 7285<br \/>\nIFM\/FI-LMC\/LYSA<br \/>\nFRANCIM<br \/>\nIMWG\/IMF<br \/>\nCentre de r\u00e9f\u00e9rence de l&rsquo;Amylose AL<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbDomaines de recherche\u00a0\u00bb tab_id=\u00a0\u00bb1779456766890-d4474de8-c6fc\u00a0\u00bb][vc_custom_heading text=\u00a0\u00bbRegistre\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_column_text]Parcours des patients[\/vc_column_text][vc_separator border_width=\u00a0\u00bb5&Prime; el_width=\u00a0\u00bb50&Prime;][vc_custom_heading text=\u00a0\u00bbP\u00e9diatrie\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_column_text]Registre international de leuc\u00e9mie my\u00e9lo\u00efde chronique (LMC) de l\u2019enfant[\/vc_column_text][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbLire l&rsquo;article\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fwp-content%2Fuploads%2F2024%2F07%2FICMLPed-Internet-Juillet2024.pdf||target:%20_blank|\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbRead the article\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fwp-content%2Fuploads%2F2024%2F07%2FICMLPed-internet-July2024.pdf||target:%20_blank|\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_separator border_width=\u00a0\u00bb5&Prime; el_width=\u00a0\u00bb50&Prime;][vc_custom_heading text=\u00a0\u00bbOncologie m\u00e9dicale\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb2\/3&Prime;][vc_column_text]Essais th\u00e9rapeutiques phase pr\u00e9coce 0 \u00e0 phase IV[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-users\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1596005715096{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#bd3937&Prime;][vc_column_text]\n<p style=\"text-align: center;\">PRODICE (EA Pr L Tapon Karayan)<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_separator border_width=\u00a0\u00bb5&Prime; el_width=\u00a0\u00bb50&Prime;][vc_custom_heading text=\u00a0\u00bbH\u00e9matologie\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb2\/3&Prime;][vc_column_text]Essais th\u00e9rapeutiques phase pr\u00e9coce 0 \u00e0 phase IV[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-users\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1596005715096{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#bd3937&Prime;][vc_column_text]\n<p style=\"text-align: center;\">Inserm U1082 Irati (Pr Gombert et Dr Herbelin)<br \/>\n2RCT Pr S\u00e9it\u00e9<br \/>\nPr Macchi et Dr Bouyer<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_separator border_width=\u00a0\u00bb5&Prime; el_width=\u00a0\u00bb50&Prime;][vc_custom_heading text=\u00a0\u00bbComplications r\u00e9nales des gammapathies monoclonales et du my\u00e9lome\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb2\/3&Prime;][vc_single_image image=\u00a0\u00bb305&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1615898135716{margin: 10px !important;background-color: #ebebeb !important;}\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb2\/3&Prime;][vc_column_text css=\u00a0\u00bb.vc_custom_1615898109641{background-color: #ebebeb !important;}\u00a0\u00bb]\n<ul>\n<li>Amylose AL et autres maladies par d\u00e9p\u00f4ts d\u2019immunoglobulines monoclonales\n<ul>\n<li>Essais th\u00e9rapeutiques<\/li>\n<li>D\u00e9veloppement de nouveaux outils diagnostiques (prot\u00e9omique, s\u00e9quen\u00e7age haut d\u00e9bit)<\/li>\n<\/ul>\n<\/li>\n<li>N\u00e9phropathie \u00e0 cylindres my\u00e9lomateux\n<ul>\n<li>Etudes des m\u00e9canismes physiopathologiques<\/li>\n<li>Essais th\u00e9rapeutiques<\/li>\n<li>Techniques d\u2019\u00e9puration des cha\u00eenes l\u00e9g\u00e8res<\/li>\n<\/ul>\n<\/li>\n<li>Autogreffe chez les patients insuffisants r\u00e9naux<\/li>\n<li>Pharmacologie des chimioth\u00e9rapies en situation d\u2019insuffisance r\u00e9nale<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_single_image image=\u00a0\u00bb307&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1615898178596{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb][vc_column_text]\n<p style=\"text-align: center;\"><em>Amylose glom\u00e9rulaire (apr\u00e8s coloration au Rouge Congo et examen en lumi\u00e8re polaris\u00e9e)<\/em><\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-users\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1596005715096{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#bd3937&Prime;][vc_column_text]\n<p style=\"text-align: center;\"><strong>Collaborations<\/strong><\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00a0\u00bbtop\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text]\n<p style=\"text-align: center;\">UMR Inserm 1262 \u2013 UMR CNRS 7276 (M Cogne &amp; C Sirac)<\/p>\n<p style=\"text-align: center;\">Fili\u00e8re de sant\u00e9 Maladies Rares Immuno-H\u00e9matologiques (MARIH)<\/p>\n<p style=\"text-align: center;\">Intergroupe Francophone du My\u00e9lome (IFM)<\/p>\n<p style=\"text-align: center;\">EuroBloodNet<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text]\n<p style=\"text-align: center;\">International Kidney and Monoclonal Gammopathy Working Group<\/p>\n<p style=\"text-align: center;\">Departments of Nephrology, Hematology and Pathology, Mayo Clinic, Rochester, USA (N Leung &amp; S Nasr)<\/p>\n<p style=\"text-align: center;\">International Society of Amyloidosis<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbEntrep\u00f4t de donn\u00e9es de sant\u00e9 international des leuc\u00e9mies my\u00e9lo\u00efdes chroniques de l&rsquo;enfant et de l&rsquo;adolescent (EDS I-CML-Pedia)\u00a0\u00bb tab_id=\u00a0\u00bb1595582696232-9e79c2cf-69e9&Prime;][vc_custom_heading text=\u00a0\u00bbR\u00e9sum\u00e9\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458619325{margin-bottom: 20px !important;}\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbT\u00e9l\u00e9charger le r\u00e9sum\u00e9 (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FResume-francais.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbDownload abstract (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FResume-anglais.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=\u00a0\u00bbNotices d&rsquo;information\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458861061{margin-bottom: 20px !important;}\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbNotice d&rsquo;information pour les professionnels de sant\u00e9 (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Professionnel_v1Final.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbDownload information letter for healthcare professionals (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Professionnel_v1Final.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbNotice d&rsquo;information pour les patients mineurs (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Mineur_v1Finale.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbDownload information letter for minors (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Minor_v1Final.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbNotice d&rsquo;information pour les patients devenus majeurs (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Majeur_v1Finale.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbDownload information letter for patients who have reached the age of majority (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_Major_v1Final.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbNotice d&rsquo;information pour les parents (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_AutoriteParentale_v1Finale.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbDownload information letter for parents (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2F20260424_EDS-I-CML-PED_LI_ParentalAutority_v1Final.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=\u00a0\u00bbGouvernance\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458629398{margin-bottom: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]Afin de v\u00e9rifier le respect des finalit\u00e9s poursuivies, le CHU de Poitiers, en tant que responsable de traitement de l&rsquo;entrep\u00f4t de donn\u00e9es I-CML-Ped, met en place une gouvernance structur\u00e9e autour de deux instances :<\/p>\n<ul>\n<li>Un comit\u00e9 de pilotage est charg\u00e9 de d\u00e9finir les orientations scientifiques et strat\u00e9giques de l&rsquo;entrep\u00f4t I-CML-Ped.<\/li>\n<li>Un comit\u00e9 scientifique et \u00e9thique, compos\u00e9 de mani\u00e8re \u00e0 garantir la diversit\u00e9 des comp\u00e9tences en mati\u00e8re de recherche dans les domaines de la sant\u00e9, est charg\u00e9 de donner syst\u00e9matiquement un avis pr\u00e9alable et motiv\u00e9 sur les propositions de projets n\u00e9cessitant la r\u00e9utilisation des donn\u00e9es de l&rsquo;entrep\u00f4t de donn\u00e9es I-CML-Ped.<\/li>\n<\/ul>\n[\/vc_column_text][vc_btn title=\u00a0\u00bbGovernance (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FGOUVERNANCE-anglais.pdf|target:_blank\u00a0\u00bb][vc_custom_heading text=\u00a0\u00bbCentres participants\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458634421{margin-bottom: 20px !important;}\u00a0\u00bb][vc_btn title=\u00a0\u00bbParticipating centers (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FPARTICIPATING-CENTERS.pdf|target:_blank\u00a0\u00bb][vc_custom_heading text=\u00a0\u00bb\u00c9tudes en cours sur les donn\u00e9es de l&rsquo;EDS I-CML-Ped\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458638788{margin-bottom: 20px !important;}\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbEtudes en cours (FR)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F06%2FETUDES-EN-COURS-EN-2026.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbStudies in progress (EN)\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FSTUDIES-IN-PROGRESS-IN-2026.pdf|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=\u00a0\u00bbArticles r\u00e9cemment publi\u00e9s\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779459145051{margin-bottom: 20px !important;}\u00a0\u00bb][vc_btn title=\u00a0\u00bbConsulter la liste des articles\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2026%2F05%2FArticles-recemment-publies.pdf|target:_blank\u00a0\u00bb][vc_custom_heading text=\u00a0\u00bbLiens utiles\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_btn title=\u00a0\u00bbLMC France\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb button_block=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.lmc-france.fr%2F|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_btn title=\u00a0\u00bbInternational BFM Study Group\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb button_block=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fbfminternational.wordpress.com%2Fstructure%2Fcommittees%2Fchronic-myeloid-leukemia-committee-cml%2F|target:_blank\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/3&Prime;][vc_btn title=\u00a0\u00bbHealth Data Hub\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb button_block=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.health-data-hub.fr%2Fprojets|target:_blank\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=\u00a0\u00bbContacts\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:center|color:%23111111&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1779458643798{margin-bottom: 20px !important;}\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n<p style=\"text-align: center;\">Pr Fr\u00e9d\u00e9ric Millot &#8211; Coordinateur<br \/>\n<a href=\"mailto:frederic.millot@chu-poitiers.fr\">frederic.millot@chu-poitiers.fr<\/a><br \/>\n+335 49 44 30 78<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n<p style=\"text-align: center;\">Micheline KABORE &#8211; Attach\u00e9e de recherche clinique<br \/>\n<a href=\"mailto:barkwende-mecheline.kabore@chu-poitiers.fr\">barkwende-mecheline.kabore@chu-poitiers.fr<\/a><br \/>\n<a href=\"mailto:icmlped@chu-poitiers.fr\">icmlped@chu-poitiers.fr<\/a><br \/>\n+335 49 44 30 57<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbMembres\u00a0\u00bb tab_id=\u00a0\u00bb1595408684037-856ac559-8cb4&Prime;][vc_custom_heading text=\u00a0\u00bbResponsable\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_column_text]Pr Xavier Leleu[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbChercheurs\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][vc_column_text]Pr Nicolas Isambert[\/vc_column_text][vc_column_text]Pr Pierre Ingrand[\/vc_column_text][vc_column_text]Dr VIncent Javaugue[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][vc_column_text]Pr Fran\u00e7ois Guilhot[\/vc_column_text][vc_column_text]Dr Vincent Delwail[\/vc_column_text][vc_column_text]Dr C\u00e9cile Tomowiak[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][vc_column_text]Pr Fr\u00e9d\u00e9ric Millot[\/vc_column_text][vc_column_text]Dr Emilie Cayssials[\/vc_column_text][vc_column_text]Dr Jos\u00e9 Miguel Torregrosa[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][vc_column_text]Pr Frank Bridoux[\/vc_column_text][vc_column_text]Dr St\u00e9phanie Guidez[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbPublications\u00a0\u00bb tab_id=\u00a0\u00bb1595408684063-ecbf3977-d27f\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n<h3><span style=\"color: #bd3937;\">2026<\/span><\/h3>\n<p>Fr\u00e9d\u00e9ric Millot, Morgane Froment, Lisa Durocher, Markus Metzler,Barbara De Moerloose,Silvia Regina Brandalise, Marina Borisevich, Adalet Meral Gunes. \u00ab\u00a0Characteristics and Outcomes of Adolescents (15\u201318 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML\u00a0\u00bb <em>Cancers<\/em>, 16\/06\/2026. <a href=\"https:\/\/doi.org\/10.3390\/cancers18121959\">https:\/\/doi.org\/10.3390\/cancers18121959<\/a><\/p>\n<h3><span style=\"color: #bd3937;\">2025<\/span><\/h3>\n<p>Fr\u00e9d\u00e9ric Millot, Joe de Keizer, Markus Metzler, Krzysztof Kalwak, Adalet Meral G\u00fcnes, Barbara De Moerloose, Maaike Luesink, Antonio Molines Honrubia.\u00a0\u00bbChildren with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML\u00a0\u00bb <em>Haematologica<\/em>, 23\/10\/2025. <a href=\"https:\/\/doi.org\/10.3324\/haematol.2025.288283\">https:\/\/doi.org\/10.3324\/haematol.2025.288283<\/a><\/p>\n<p class=\"c-article-title\" data-test=\"article-title\">Fr\u00e9d\u00e9ric Millot, Mirella Ampatzidou, Nirmalya Roy Moulik, Sanjay Tewari, Alaa Elhaddad, Mahmoud Hammad, Herbert Pichler, Thomas Lion. \u00ab\u00a0Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations\u00a0\u00bb . <em>Leukemia<\/em>, 05\/03\/2025. <a href=\"https:\/\/www.nature.com\/articles\/s41375-025-02543-4\">https:\/\/www.nature.com\/articles\/s41375-025-02543-4<\/a><\/p>\n<h3><span style=\"color: #bd3937;\">2020<\/span><\/h3>\n<p>Barbarin, Alice, Myriam Abdallah, Lucie Lef\u00e8vre, Nathalie Piccirilli, Emilie Cayssials, Lydia Roy, Jean-Marc Gombert, et Andr\u00e9 Herbelin. \u00ab\u00a0Innate T-\u0391\u03b2 Lymphocytes as New Immunological Components of Anti-Tumoral \u201coff-Target\u201d Effects of the Tyrosine Kinase Inhibitor Dasatinib\u00a0\u00bb. <em>Scientific Reports<\/em> 10, n<sup>o<\/sup> 1 (24 f\u00e9vrier 2020): 3245. <a href=\"https:\/\/doi.org\/10.1038\/s41598-020-60195-z\">https:\/\/doi.org\/10.1038\/s41598-020-60195-z<\/a>.<\/p>\n<p>Bender, S\u00e9bastien, Vincent Javaugue, Alexis Saintamand, Maria Victoria Ayala, Mehdi Alizadeh, Matthieu Filloux, Virginie Pascal, et al. \u00ab\u00a0Immunoglobulin Variable Domain High-Throughput Sequencing Reveals Specific Novel Mutational Patterns in POEMS Syndrome\u00a0\u00bb. <em>Blood<\/em> 135, n<sup>o<\/sup> 20 (14 mai 2020): 1750\u201158. <a href=\"https:\/\/doi.org\/10.1182\/blood.2019004197\">https:\/\/doi.org\/10.1182\/blood.2019004197<\/a>.<\/p>\n<p>H\u00e4hnel, Tom, Christoph Baldow, Jo\u00eblle Guilhot, Fran\u00e7ois Guilhot, Susanne Saussele, Satu Mustjoki, Stefanie Jilg, et al. \u00ab\u00a0Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML\u00a0\u00bb. <em>Cancer Research<\/em> 80, n<sup>o<\/sup> 11 (1 juin 2020): 2394\u20112406. <a href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2175\">https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2175<\/a>.<\/p>\n<p>Hochhaus, A., M. Baccarani, R. T. Silver, C. Schiffer, J. F. Apperley, F. Cervantes, R. E. Clark, et al. \u00ab\u00a0European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia\u00a0\u00bb. <em>Leukemia<\/em> 34, n<sup>o<\/sup> 4 (avril 2020): 966\u201184. <a href=\"https:\/\/doi.org\/10.1038\/s41375-020-0776-2\">https:\/\/doi.org\/10.1038\/s41375-020-0776-2<\/a>.<\/p>\n<p>Narquin, S., P. Ingrand, I. Azais, V. Delwail, R. Vialle, S. Boucebci, et J.-P. Tasu. \u00ab\u00a0Erratum to \u201cComparison of Whole-Body Diffusion MRI Andconventional Radiological Assessment in the Staging of Myeloma\u201d [Diagn. Interv. Imaging. 94 (2013), 629-636]\u00a0\u00bb. <em>Diagnostic and Interventional Imaging<\/em> 101, n<sup>o<\/sup> 5 (2020): 331. <a href=\"https:\/\/doi.org\/10.1016\/j.diii.2019.12.012\">https:\/\/doi.org\/10.1016\/j.diii.2019.12.012<\/a>.<\/p>\n<p>Pladys, Ad\u00e9la\u00efde, Gautier Defossez, Pierre Lemordant, Mathilde Lassalle, Pierre Ingrand, Christian Jacquelinet, Christine Riou, et al. \u00ab\u00a0Cancer Risk in Dialyzed Patients with and without Diabetes\u00a0\u00bb. <em>Cancer Epidemiology<\/em> 65 (avril 2020): 101689. <a href=\"https:\/\/doi.org\/10.1016\/j.canep.2020.101689\">https:\/\/doi.org\/10.1016\/j.canep.2020.101689<\/a>.<\/p>\n<p>Roussel, Murielle, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Anne-Marie Stoppa, Margaret Macro, et al. \u00ab\u00a0Health-Related Quality of Life Results from the IFM 2009 Trial: Treatment with Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 61, n<sup>o<\/sup> 6 (juin 2020): 1323\u201133. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2020.1719091\">https:\/\/doi.org\/10.1080\/10428194.2020.1719091<\/a>.<\/p>\n<p>Roussel, Murielle, Giampaolo Merlini, Sylvie Chevret, Bertrand Arnulf, Anne Marie Stoppa, Aurore Perrot, Giovanni Palladini, et al. \u00ab\u00a0A Prospective Phase 2 Trial of Daratumumab in Patients with Previously Treated Systemic Light-Chain Amyloidosis\u00a0\u00bb. <em>Blood<\/em> 135, n<sup>o<\/sup> 18 (30 avril 2020): 1531\u201140. <a href=\"https:\/\/doi.org\/10.1182\/blood.2019004369\">https:\/\/doi.org\/10.1182\/blood.2019004369<\/a>.<\/p>\n<p>S\u00f6derlund, Stina, Inger Persson, Mette Ilander, Jo\u00eblle Guilhot, Henrik Hjorth-Hansen, Perttu Koskenvesa, Johan Richter, Susanne Saussele, Satu Mustjoki, et Ulla Olsson-Str\u00f6mberg. \u00ab\u00a0Plasma Proteomics of Biomarkers for Inflammation or Cancer Cannot Predict Relapse in Chronic Myeloid Leukaemia Patients Stopping Tyrosine Kinase Inhibitor Therapy\u00a0\u00bb. <em>Leukemia Research<\/em> 90 (mars 2020): 106310. <a href=\"https:\/\/doi.org\/10.1016\/j.leukres.2020.106310\">https:\/\/doi.org\/10.1016\/j.leukres.2020.106310<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><span style=\"color: #bd3937;\">2019<\/span><\/h3>\n<p>Attal, Michel, Paul G. Richardson, S. Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, et al. \u00ab\u00a0Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study\u00a0\u00bb. <em>Lancet (London, England)<\/em> 394, n<sup>o<\/sup> 10214 (07 2019): 2096\u20112107. <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5\">https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5<\/a>.<\/p>\n<p>Berger, Marc G., Bruno Pereira, Philippe Rousselot, Pascale Cony-Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre-Barbe, et al. \u00ab\u00a0Longer Treatment Duration and History of Osteoarticular Symptoms Predispose to Tyrosine Kinase Inhibitor Withdrawal Syndrome\u00a0\u00bb. <em>British Journal of Haematology<\/em> 187, n<sup>o<\/sup> 3 (2019): 337\u201146. <a href=\"https:\/\/doi.org\/10.1111\/bjh.16083\">https:\/\/doi.org\/10.1111\/bjh.16083<\/a>.<\/p>\n<p>Boyle, Eileen M., Xavier Leleu, Marie-Odile Petillon, Lionel Karlin, Chantal Doyen, H\u00e9l\u00e8ne Demarquette, Bruno Royer, et al. \u00ab\u00a0Daratumumab and Dexamethasone Is Safe and Effective for Triple Refractory Myeloma Patients: Final Results of the IFM 2014-04 (Etoile Du Nord) Trial\u00a0\u00bb. <em>British Journal of Haematology<\/em> 187, n<sup>o<\/sup> 3 (2019): 319\u201127. <a href=\"https:\/\/doi.org\/10.1111\/bjh.16059\">https:\/\/doi.org\/10.1111\/bjh.16059<\/a>.<\/p>\n<p>Bruijn, Clara M. A. de, Fr\u00e9d\u00e9ric Millot, Meinolf Suttorp, Marina Borisevich, Paul Brons, Birgitte Lausen, et Eveline S. J. M. de Bont. \u00ab\u00a0Discontinuation of Imatinib in Children with Chronic Myeloid Leukaemia in Sustained Deep Molecular Remission: Results of the STOP IMAPED Study\u00a0\u00bb. <em>British Journal of Haematology<\/em> 185, n<sup>o<\/sup> 4 (2019): 718\u201124. <a href=\"https:\/\/doi.org\/10.1111\/bjh.15826\">https:\/\/doi.org\/10.1111\/bjh.15826<\/a>.<\/p>\n<p>Camuset, Margaux, Audrey Grain, Fleur Lorton, Odile Minckes, Anne Jourdain, Fr\u00e9d\u00e9ric Millot, Isabelle Pellier, Virginie Gandemer, et Fanny Rialland Battisti. \u00ab\u00a0[Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion: A chance for all]\u00a0\u00bb. <em>Bulletin Du Cancer<\/em> 106, n<sup>o<\/sup> 3 (mars 2019): 206\u201115. <a href=\"https:\/\/doi.org\/10.1016\/j.bulcan.2018.11.012\">https:\/\/doi.org\/10.1016\/j.bulcan.2018.11.012<\/a>.<\/p>\n<p>Chaoui, Driss, Maya Hacini, Olivier Fitoussi, Lionel Karlin, Yazid Arkam, Eric Jourdan, Hubert Orfeuvre, et al. \u00ab\u00a0Relapsed or Refractory Chronic Lymphocytic Leukemia Retreated with Rituximab in Daily Practice: Final Results of the PERLE Study\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 60, n<sup>o<\/sup> 6 (2019): 1563\u201167. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2018.1533130\">https:\/\/doi.org\/10.1080\/10428194.2018.1533130<\/a>.<\/p>\n<p>Chiche, Johanna, Julie Reverso-Meinietti, Annabelle Mouchotte, Camila Rubio-Pati\u00f1o, Rana Mhaidly, Elodie Villa, Jozef P. Bossowski, et al. \u00ab\u00a0GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors\u00a0\u00bb. <em>Cell Metabolism<\/em> 29, n<sup>o<\/sup> 6 (04 2019): 1243-1257.e10. <a href=\"https:\/\/doi.org\/10.1016\/j.cmet.2019.02.002\">https:\/\/doi.org\/10.1016\/j.cmet.2019.02.002<\/a>.<\/p>\n<p>Coignard-Biehler, H\u00e9l\u00e8ne, Nizar Mahlaoui, Benoit Pilmis, Vincent Barlogis, Pauline Brosselin, Nathalie De Vergnes, Marianne Debr\u00e9, et al. \u00ab\u00a0A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency\u00a0\u00bb. <em>Journal of Clinical Immunology<\/em> 39, n<sup>o<\/sup> 7 (2019): 702\u201112. <a href=\"https:\/\/doi.org\/10.1007\/s10875-019-00658-9\">https:\/\/doi.org\/10.1007\/s10875-019-00658-9<\/a>.<\/p>\n<p>Costello, Caitlin, Faith E. Davies, Gordon Cook, Jorge Vela-Ojeda, Jim Omel, Robert M. Rifkin, Jesus Berdeja, et al. \u00ab\u00a0INSIGHT MM: A Large, Global, Prospective, Non-Interventional, Real-World Study of Patients with Multiple Myeloma\u00a0\u00bb. <em>Future Oncology (London, England)<\/em> 15, n<sup>o<\/sup> 13 (mai 2019): 1411\u201128. <a href=\"https:\/\/doi.org\/10.2217\/fon-2019-0013\">https:\/\/doi.org\/10.2217\/fon-2019-0013<\/a>.<\/p>\n<p>Facon, Thierry, Meletios A. Dimopoulos, Nathalie Meuleman, Andrew Belch, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, et al. \u00ab\u00a0A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM-020) Trial\u00a0\u00bb. <em>Leukemia<\/em> 34, n<sup>o<\/sup> 1 (2020): 224\u201133. <a href=\"https:\/\/doi.org\/10.1038\/s41375-019-0539-0\">https:\/\/doi.org\/10.1038\/s41375-019-0539-0<\/a>.<\/p>\n<p>Facon, Thierry, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, et al. \u00ab\u00a0Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma\u00a0\u00bb. <em>The New England Journal of Medicine<\/em> 380, n<sup>o<\/sup> 22 (30 2019): 2104\u201115. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1817249\">https:\/\/doi.org\/10.1056\/NEJMoa1817249<\/a>.<\/p>\n<p>Gallego Hernanz, Maria Pilar, Jos\u00e9 Miguel Torregrosa Diaz, Nathalie Sorel, Arthur Bobin, Elodie Dindinaud, Sabrina Bouyer, Deborah Desmier, et al. \u00ab\u00a0Long-Term Molecular Remission in a Patient with Acute Myeloid Leukemia Harboring a New NUP98-LEDGF Rearrangement\u00a0\u00bb. <em>Cancer Medicine<\/em> 8, n<sup>o<\/sup> 4 (2019): 1765\u201170. <a href=\"https:\/\/doi.org\/10.1002\/cam4.2051\">https:\/\/doi.org\/10.1002\/cam4.2051<\/a>.<\/p>\n<p>Guidez, Stephanie, Laurence Lacotte-Thierry, Cecile Tomowiak, Isabelle Princet, Brigitte Dreyfus, Gaelle Olivier, Emmanuel Fleck, et al. \u00ab\u00a0Oral CHOP-like Chemotherapy in 60-80\u00a0Years-Old Patients with Diffuse Large B-Cell Lymphoma\u00a0\u00bb. <em>British Journal of Haematology<\/em> 186, n<sup>o<\/sup> 6 (2019): e175\u201178. <a href=\"https:\/\/doi.org\/10.1111\/bjh.16056\">https:\/\/doi.org\/10.1111\/bjh.16056<\/a>.<\/p>\n<p>Guilhot, Fran\u00e7ois. \u00ab\u00a0Ponatinib and Platelets a Conflict in CML\u00a0\u00bb. <em>Blood<\/em> 133, n<sup>o<\/sup> 14 (04 2019): 1520\u201121. <a href=\"https:\/\/doi.org\/10.1182\/blood-2019-02-900472\">https:\/\/doi.org\/10.1182\/blood-2019-02-900472<\/a>.<\/p>\n<p>Hadjadj, J\u00e9r\u00f4me, Nathalie Aladjidi, Helder Fernandes, Guy Leverger, Aude Mag\u00e9rus-Chatinet, Fabienne Mazerolles, Marie-Claude Stolzenberg, et al. \u00ab\u00a0Pediatric Evans Syndrome Is Associated with a High Frequency of Potentially Damaging Variants in Immune Genes\u00a0\u00bb. <em>Blood<\/em> 134, n<sup>o<\/sup> 1 (04 2019): 9\u201121. <a href=\"https:\/\/doi.org\/10.1182\/blood-2018-11-887141\">https:\/\/doi.org\/10.1182\/blood-2018-11-887141<\/a>.<\/p>\n<p>Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, et al. \u00ab\u00a0Phase 2 Study of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia\u00a0\u00bb. <em>Blood<\/em> 134, n<sup>o<\/sup> 23 (05 2019): 2036\u201145. <a href=\"https:\/\/doi.org\/10.1182\/blood.2019000069\">https:\/\/doi.org\/10.1182\/blood.2019000069<\/a>.<\/p>\n<p>Hofmans, Mattias, Stefan Suciu, Alina Ferster, Pieter Van Vlierberghe, Fran\u00e7oise Mazingue, Nicolas Sirvent, Vitor Costa, et al. \u00ab\u00a0Results of Successive EORTC-CLG 58\u00a0881 and 58\u00a0951 Trials in Paediatric T-Cell Acute Lymphoblastic Leukaemia (ALL)\u00a0\u00bb. <em>British Journal of Haematology<\/em> 186, n<sup>o<\/sup> 5 (2019): 741\u201153. <a href=\"https:\/\/doi.org\/10.1111\/bjh.15983\">https:\/\/doi.org\/10.1111\/bjh.15983<\/a>.<\/p>\n<p>Horwitz, Steven, Owen A. O\u2019Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, et al. \u00ab\u00a0Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial\u00a0\u00bb. <em>Lancet (London, England)<\/em> 393, n<sup>o<\/sup> 10168 (19 2019): 229\u201140. <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2\">https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2<\/a>.<\/p>\n<p>Houillier, Caroline, Luc Taillandier, Sylvain Dureau, Thierry Lamy, Mouna Laadhari, Olivier Chinot, Cecile Molu\u00e7on-Chabrot, et al. \u00ab\u00a0Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study\u00a0\u00bb. <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/em> 37, n<sup>o<\/sup> 10 (01 2019): 823\u201133. <a href=\"https:\/\/doi.org\/10.1200\/JCO.18.00306\">https:\/\/doi.org\/10.1200\/JCO.18.00306<\/a>.<\/p>\n<p>Ingrand, Isabelle, Ludovic Gaussot, Elisabeth Richard, Griselda Drouet, Fabienne Moreau, et Pierre Ingrand. \u00ab\u00a0[Family risk information for colorectal cancer. Perspectives on the effectiveness of a tailored intervention]\u00a0\u00bb. <em>Sante Publique (Vandoeuvre-Les-Nancy, France)<\/em> S2, n<sup>o<\/sup> HS2 (2019): 79\u201189. <a href=\"https:\/\/doi.org\/10.3917\/spub.197.0079\">https:\/\/doi.org\/10.3917\/spub.197.0079<\/a>.<\/p>\n<p>Lacourt, Aude, Brice Amad\u00e9o, C\u00e9line Gramond, Emilie Marrer, Sandrine Plouvier, Isabelle Baldi, Jean-Yves Blay, et al. \u00ab\u00a0ETIOSARC Study\u202f: Environmental Aetiology of Sarcomas from a French Prospective Multicentric Population-Based Case-Control Study-Study Protocol\u00a0\u00bb. <em>BMJ Open<\/em> 9, n<sup>o<\/sup> 6 (18 2019): e030013. <a href=\"https:\/\/doi.org\/10.1136\/bmjopen-2019-030013\">https:\/\/doi.org\/10.1136\/bmjopen-2019-030013<\/a>.<\/p>\n<p>Lauseker, Michael, Katharina Bachl, Anna Turkina, Edgar Faber, Witold Prejzner, Ulla Olsson-Str\u00f6mberg, Michele Baccarani, et al. \u00ab\u00a0Prognosis of Patients with Chronic Myeloid Leukemia Presenting in Advanced Phase Is Defined Mainly by Blast Count, but Also by Age, Chromosomal Aberrations and Hemoglobin\u00a0\u00bb. <em>American Journal of Hematology<\/em> 94, n<sup>o<\/sup> 11 (2019): 1236\u201143. <a href=\"https:\/\/doi.org\/10.1002\/ajh.25628\">https:\/\/doi.org\/10.1002\/ajh.25628<\/a>.<\/p>\n<p>Leleu, Xavier, Guillemette Fouquet, Valentine Richez, St\u00e9phanie Guidez, Alain Duhamel, Fran\u00e7ois Machuron, Lionel Karlin, et al. \u00ab\u00a0Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial\u00a0\u00bb. <em>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research<\/em> 25, n<sup>o<\/sup> 14 (15 2019): 4224\u201130. <a href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3642\">https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3642<\/a>.<\/p>\n<p>Mahamdallie, Shazia, Shawn Yost, Emma Poyastro-Pearson, Esty Holt, Anna Zachariou, Sheila Seal, Anna Elliott, et al. \u00ab\u00a0Identification of New Wilms Tumour Predisposition Genes: An Exome Sequencing Study\u00a0\u00bb. <em>The Lancet. Child &amp; Adolescent Health<\/em> 3, n<sup>o<\/sup> 5 (2019): 322\u201131. <a href=\"https:\/\/doi.org\/10.1016\/S2352-4642(19)30018-5\">https:\/\/doi.org\/10.1016\/S2352-4642(19)30018-5<\/a>.<\/p>\n<p>Millot, Fr\u00e9d\u00e9ric, Natacha Maledon, Joelle Guilhot, Adalet Meral G\u00fcne\u015f, Krzysztof Kalwak, et Meinolf Suttorp. \u00ab\u00a0Favourable Outcome of de Novo Advanced Phases of Childhood Chronic Myeloid Leukaemia\u00a0\u00bb. <em>European Journal of Cancer (Oxford, England: 1990)<\/em> 115 (2019): 17\u201123. <a href=\"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.020\">https:\/\/doi.org\/10.1016\/j.ejca.2019.03.020<\/a>.<\/p>\n<p>Pegourie, Brigitte, Lionel Karlin, Lotfi Benboubker, Fr\u00e9d\u00e9rique Orsini-Piocelle, Mourad Tiab, Sophie Auger-Quittet, Philippe Rodon, et al. \u00ab\u00a0Apixaban for the Prevention of Thromboembolism in Immunomodulatory-Treated Myeloma Patients: Myelaxat, a Phase 2 Pilot Study\u00a0\u00bb. <em>American Journal of Hematology<\/em> 94, n<sup>o<\/sup> 6 (2019): 635\u201140. <a href=\"https:\/\/doi.org\/10.1002\/ajh.25459\">https:\/\/doi.org\/10.1002\/ajh.25459<\/a>.<\/p>\n<p>Pertesi, Maroulio, Maxime Vall\u00e9e, Xiaomu Wei, Maria V. Revuelta, Perrine Galia, Delphine Demangel, Javier Oliver, et al. \u00ab\u00a0Exome Sequencing Identifies Germline Variants in DIS3 in Familial Multiple Myeloma\u00a0\u00bb. <em>Leukemia<\/em> 33, n<sup>o<\/sup> 9 (2019): 2324\u201130. <a href=\"https:\/\/doi.org\/10.1038\/s41375-019-0452-6\">https:\/\/doi.org\/10.1038\/s41375-019-0452-6<\/a>.<\/p>\n<p>Pincez, Thomas, B\u00e9n\u00e9dicte Neven, Hubert Ducou Le Pointe, Pascale Varlet, Helder Fernandes, Albane Gareton, Guy Leverger, et al. \u00ab\u00a0Neurological Involvement in Childhood Evans Syndrome\u00a0\u00bb. <em>Journal of Clinical Immunology<\/em> 39, n<sup>o<\/sup> 2 (2019): 171\u201181. <a href=\"https:\/\/doi.org\/10.1007\/s10875-019-0594-3\">https:\/\/doi.org\/10.1007\/s10875-019-0594-3<\/a>.<\/p>\n<p>Richardson, Paul G., Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, et al. \u00ab\u00a0Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial\u00a0\u00bb. <em>The Lancet. Oncology<\/em> 20, n<sup>o<\/sup> 6 (2019): 781\u201194. <a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(19)30152-4\">https:\/\/doi.org\/10.1016\/S1470-2045(19)30152-4<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<h3><span style=\"color: #bd3937;\">2018<\/span><\/h3>\n<p>Cabannes-Hamy, Aur\u00e9lie, Frederic Peyrade, Fabrice Jardin, Jean-Fran\u00e7ois Emile, Vincent Delwail, Nicolas Mounier, Corinne Haioun, et al. \u00ab\u00a0Central Nervous System Relapse in Patients over 80 Years with Diffuse Large B-Cell Lymphoma: An Analysis of Two LYSA Studies\u00a0\u00bb. <em>Cancer Medicine<\/em> 7, n<sup>o<\/sup> 3 (2018): 539\u201148. <a href=\"https:\/\/doi.org\/10.1002\/cam4.1139\">https:\/\/doi.org\/10.1002\/cam4.1139<\/a>.<\/p>\n<p>Cayssials, Emilie, Florence Tartarin, Jo\u00eblle Guilhot, Nathalie Sorel, Jean Claude Chomel, Xavier Leleu, et Fran\u00e7ois Guilhot. \u00ab\u00a0Sustained Molecular Response in Chronic Myeloid Leukemia Deep Responders Treated with Low Dose Tyrosine Kinase Inhibitors\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 59, n<sup>o<\/sup> 3 (2018): 766\u201169. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2017.1357178\">https:\/\/doi.org\/10.1080\/10428194.2017.1357178<\/a>.<\/p>\n<p>Chantepie, Sylvain P., Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie-Virginie Larcher, Momar Diouf, Luc-Mathieu Fornecker, et al. \u00ab\u00a0Bendamustine-Based Conditioning Prior to Autologous Stem Cell Transplantation (ASCT): Results of a French Multicenter Study of 474 Patients from LYmphoma Study Association (LYSA) Centers\u00a0\u00bb. <em>American Journal of Hematology<\/em> 93, n<sup>o<\/sup> 6 (juin 2018): 729\u201135. <a href=\"https:\/\/doi.org\/10.1002\/ajh.25077\">https:\/\/doi.org\/10.1002\/ajh.25077<\/a>.<\/p>\n<p>Desandes, Emmanuel, Laurence Brugi\u00e8res, Florence Molini\u00e9, Gautier Defossez, Patricia Delafosse, Karine Jehannin-Ligier, Michel Velten, et al. \u00ab\u00a0Adolescent and Young Adult Oncology Patients in France: Heterogeneity in Pathways of Care\u00a0\u00bb. <em>Pediatric Blood &amp; Cancer<\/em> 65, n<sup>o<\/sup> 9 (2018): e27235. <a href=\"https:\/\/doi.org\/10.1002\/pbc.27235\">https:\/\/doi.org\/10.1002\/pbc.27235<\/a>.<\/p>\n<p>Dimopoulos, Meletios, Katja Weisel, Niels W. C. J. van de Donk, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, et al. \u00ab\u00a0Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial\u00a0\u00bb. <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/em> 36, n<sup>o<\/sup> 20 (10 2018): 2035\u201143. <a href=\"https:\/\/doi.org\/10.1200\/JCO.2017.76.1742\">https:\/\/doi.org\/10.1200\/JCO.2017.76.1742<\/a>.<\/p>\n<p>Facon, Thierry, Meletios A. Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew Belch, Michele Cavo, Antonello Pinto, et al. \u00ab\u00a0Final Analysis of Survival Outcomes in the Phase 3 FIRST Trial of Up-Front Treatment for Multiple Myeloma\u00a0\u00bb. <em>Blood<\/em> 131, n<sup>o<\/sup> 3 (18 2018): 301\u201110. <a href=\"https:\/\/doi.org\/10.1182\/blood-2017-07-795047\">https:\/\/doi.org\/10.1182\/blood-2017-07-795047<\/a>.<\/p>\n<p>Fouquet, Guillemette, Kym Ie Snell, St\u00e9phanie Guidez, Susanna Schraen, Eileen Boyle, Lo\u00efc Renaud, D\u00e9borah Desmier, et al. \u00ab\u00a0Heavy\u2009+\u2009Light Chain Analysis to Assign Myeloma Response Is Analogous to the IMWG Response Criteria\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 59, n<sup>o<\/sup> 3 (2018): 583\u201189. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2017.1339876\">https:\/\/doi.org\/10.1080\/10428194.2017.1339876<\/a>.<\/p>\n<p>Garderet, Laurent, Simona Iacobelli, Linda Koster, Hartmut Goldschmidt, Jan-Erik Johansson, Jean Henri Bourhis, Marta Krejci, et al. \u00ab\u00a0Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma\u00a0\u00bb. <em>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation<\/em> 24, n<sup>o<\/sup> 7 (2018): 1372\u201178. <a href=\"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.035\">https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.035<\/a>.<\/p>\n<p>Jurczyszyn, Artur, Jakub Radocha, Julio Davila, Mark A. Fiala, Alessandro Gozzetti, Norbert Grz\u0105\u015bko, Pawe\u0142 Robak, et al. \u00ab\u00a0Prognostic Indicators in Primary Plasma Cell Leukaemia: A Multicentre Retrospective Study of 117 Patients\u00a0\u00bb. <em>British Journal of Haematology<\/em> 180, n<sup>o<\/sup> 6 (2018): 831\u201139. <a href=\"https:\/\/doi.org\/10.1111\/bjh.15092\">https:\/\/doi.org\/10.1111\/bjh.15092<\/a>.<\/p>\n<p>Lamy, Thierry, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, Krimo Bouabdallah, R\u00e9my Gressin, et al. \u00ab\u00a0R-CHOP 14 with or without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma\u00a0\u00bb. <em>Blood<\/em> 131, n<sup>o<\/sup> 2 (11 2018): 174\u201181. <a href=\"https:\/\/doi.org\/10.1182\/blood-2017-07-793984\">https:\/\/doi.org\/10.1182\/blood-2017-07-793984<\/a>.<\/p>\n<p>Ludwig, Heinz, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay, Philippe Moreau, Herv\u00e9 Avet-Loiseau, et al. \u00ab\u00a0Prevention and Management of Adverse Events of Novel Agents in Multiple Myeloma: A Consensus of the European Myeloma Network\u00a0\u00bb. <em>Leukemia<\/em> 32, n<sup>o<\/sup> 7 (2018): 1542\u201160. <a href=\"https:\/\/doi.org\/10.1038\/s41375-018-0040-1\">https:\/\/doi.org\/10.1038\/s41375-018-0040-1<\/a>.<\/p>\n<p>Saussele, Susanne, Johan Richter, Joelle Guilhot, Franz X. Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J. W. M. Janssen, et al. \u00ab\u00a0Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO-SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non-Randomised, Trial\u00a0\u00bb. <em>The Lancet. Oncology<\/em> 19, n<sup>o<\/sup> 6 (2018): 747\u201157. <a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X\">https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><span style=\"color: #bd3937;\">2017<\/span><\/h3>\n<p>Aggoune, Djamel, Nathalie Sorel, Marie-Laure Bonnet, Jean-Michel Goujon, Karin Tarte, Olivier H\u00e9rault, Jorge Domenech, et al. \u00ab\u00a0Bone Marrow Mesenchymal Stromal Cell (MSC) Gene Profiling in Chronic Myeloid Leukemia (CML) Patients at Diagnosis and in Deep Molecular Response Induced by Tyrosine Kinase Inhibitors (TKIs)\u00a0\u00bb. <em>Leukemia Research<\/em> 60 (2017): 94\u2011102. <a href=\"https:\/\/doi.org\/10.1016\/j.leukres.2017.07.007\">https:\/\/doi.org\/10.1016\/j.leukres.2017.07.007<\/a>.<\/p>\n<p>Attal, Michel, Valerie Lauwers-Cances, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, et al. \u00ab\u00a0Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma\u00a0\u00bb. <em>The New England Journal of Medicine<\/em> 376, n<sup>o<\/sup> 14 (06 2017): 1311\u201120. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1611750\">https:\/\/doi.org\/10.1056\/NEJMoa1611750<\/a>.<\/p>\n<p>Barbarin, Alice, Emilie Cayssials, Florence Jacomet, Nicolas Gonzalo Nunez, Sara Basbous, Lucie Lef\u00e8vre, Myriam Abdallah, et al. \u00ab\u00a0Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases\u00a0\u00bb. <em>Frontiers in Immunology<\/em> 8 (2017): 316. <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2017.00316\">https:\/\/doi.org\/10.3389\/fimmu.2017.00316<\/a>.<\/p>\n<p>Breccia, Massimo, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, Fran\u00e7ois Guilhot, Marco Vignetti, et Fabio Efficace. \u00ab\u00a0Physicians\u2019 Attitude towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients\u00a0\u00bb. <em>Health and Quality of Life Outcomes<\/em> 15, n<sup>o<\/sup> 1 (18 octobre 2017): 204. <a href=\"https:\/\/doi.org\/10.1186\/s12955-017-0788-4\">https:\/\/doi.org\/10.1186\/s12955-017-0788-4<\/a>.<\/p>\n<p>Chaoui, Driss, Sylvain Choquet, Laurence Sanhes, B\u00e9atrice Mah\u00e9, Maya Hacini, Olivier Fitoussi, Yazid Arkam, et al. \u00ab\u00a0Relapsed Chronic Lymphocytic Leukemia Retreated with Rituximab: Interim Results of the PERLE Study\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 58, n<sup>o<\/sup> 6 (2017): 1366\u201175. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2016.1243673\">https:\/\/doi.org\/10.1080\/10428194.2016.1243673<\/a>.<\/p>\n<p>Chauvet, Sophie, V\u00e9ronique Fr\u00e9meaux-Bacchi, Florent Petitprez, Alexandre Karras, Laurent Daniel, St\u00e9phane Burtey, Gabriel Choukroun, et al. \u00ab\u00a0Treatment of B-Cell Disorder Improves Renal Outcome of Patients with Monoclonal Gammopathy-Associated C3 Glomerulopathy\u00a0\u00bb. <em>Blood<\/em> 129, n<sup>o<\/sup> 11 (16 2017): 1437\u201147. <a href=\"https:\/\/doi.org\/10.1182\/blood-2016-08-737163\">https:\/\/doi.org\/10.1182\/blood-2016-08-737163<\/a>.<\/p>\n<p>Etienne, Gabriel, Jo\u00eblle Guilhot, Delphine Rea, Fran\u00e7oise Rigal-Huguet, Franck Nicolini, Aude Charbonnier, Agn\u00e8s Guerci-Bresler, et al. \u00ab\u00a0Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia\u00a0\u00bb. <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/em> 35, n<sup>o<\/sup> 3 (20 janvier 2017): 298\u2011305. <a href=\"https:\/\/doi.org\/10.1200\/JCO.2016.68.2914\">https:\/\/doi.org\/10.1200\/JCO.2016.68.2914<\/a>.<\/p>\n<p>Favreau, M., E. Menu, D. Gaublomme, K. Vanderkerken, S. Faict, K. Maes, E. De Bruyne, et al. \u00ab\u00a0Leptin Receptor Antagonism of INKT Cell Function: A Novel Strategy to Combat Multiple Myeloma\u00a0\u00bb. <em>Leukemia<\/em> 31, n<sup>o<\/sup> 12 (2017): 2678\u201185. <a href=\"https:\/\/doi.org\/10.1038\/leu.2017.146\">https:\/\/doi.org\/10.1038\/leu.2017.146<\/a>.<\/p>\n<p>Garnier, Cyrille, Fatma Briki, Brigitte Nedelec, Patrick Le Pogamp, Ahmet Dogan, Nathalie Rioux-Leclercq, Renan Goude, et al. \u00ab\u00a0VLITL Is a Major Cross-\u03b2-Sheet Signal for Fibrinogen A\u03b1-Chain Frameshift Variants\u00a0\u00bb. <em>Blood<\/em> 130, n<sup>o<\/sup> 25 (21 2017): 2799\u20112807. <a href=\"https:\/\/doi.org\/10.1182\/blood-2017-07-796185\">https:\/\/doi.org\/10.1182\/blood-2017-07-796185<\/a>.<\/p>\n<p>H\u00e1jek, R., T. Masszi, M. T. Petrucci, A. Palumbo, L. Rosi\u00f1ol, A. Nagler, K. L. Yong, et al. \u00ab\u00a0A Randomized Phase III Study of Carfilzomib vs Low-Dose Corticosteroids with Optional Cyclophosphamide in Relapsed and Refractory Multiple Myeloma (FOCUS)\u00a0\u00bb. <em>Leukemia<\/em> 31, n<sup>o<\/sup> 1 (2017): 107\u201114. <a href=\"https:\/\/doi.org\/10.1038\/leu.2016.176\">https:\/\/doi.org\/10.1038\/leu.2016.176<\/a>.<\/p>\n<p>Hochhaus, Andreas, Richard A. Larson, Fran\u00e7ois Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, et al. \u00ab\u00a0Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia\u00a0\u00bb. <em>The New England Journal of Medicine<\/em> 376, n<sup>o<\/sup> 10 (09 2017): 917\u201127. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1609324\">https:\/\/doi.org\/10.1056\/NEJMoa1609324<\/a>.<\/p>\n<p>Hoffmann, V. S., M. Baccarani, J. Hasford, F. Castagnetti, F. Di Raimondo, L. F. Casado, A. Turkina, et al. \u00ab\u00a0Treatment and Outcome of 2904 CML Patients from the EUTOS Population-Based Registry\u00a0\u00bb. <em>Leukemia<\/em> 31, n<sup>o<\/sup> 3 (2017): 593\u2011601. <a href=\"https:\/\/doi.org\/10.1038\/leu.2016.246\">https:\/\/doi.org\/10.1038\/leu.2016.246<\/a>.<\/p>\n<p>Ilander, M., U. Olsson-Str\u00f6mberg, H. Schlums, J. Guilhot, O. Br\u00fcck, H. L\u00e4hteenm\u00e4ki, T. Kasanen, et al. \u00ab\u00a0Increased Proportion of Mature NK Cells Is Associated with Successful Imatinib Discontinuation in Chronic Myeloid Leukemia\u00a0\u00bb. <em>Leukemia<\/em> 31, n<sup>o<\/sup> 5 (2017): 1108\u201116. <a href=\"https:\/\/doi.org\/10.1038\/leu.2016.360\">https:\/\/doi.org\/10.1038\/leu.2016.360<\/a>.<\/p>\n<p>Jacomet, Florence, Emilie Cayssials, Alice Barbarin, Deborah Desmier, Sara Basbous, Lucie Lef\u00e8vre, Ana\u00efs Levescot, et al. \u00ab\u00a0The Hypothesis of the Human INKT\/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia\u00a0\u00bb. <em>Frontiers in Immunology<\/em> 7 (2016): 688. <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2016.00688\">https:\/\/doi.org\/10.3389\/fimmu.2016.00688<\/a>.<\/p>\n<p>Leblond, V\u00e9ronique, Pierre Morel, Marie-Sarah Dilhuidy, Xavier Leleu, Carole Soussain, St\u00e9phane Lepr\u00eate, Brigitte Dreyfus, et al. \u00ab\u00a0A Phase II Bayesian Sequential Clinical Trial in Advanced Waldenstr\u00f6m Macroglobulinemia Patients Treated with Bortezomib: Interest of Addition of Dexamethasone\u00a0\u00bb. <em>Leukemia &amp; Lymphoma<\/em> 58, n<sup>o<\/sup> 11 (2017): 2615\u201123. <a href=\"https:\/\/doi.org\/10.1080\/10428194.2017.1307357\">https:\/\/doi.org\/10.1080\/10428194.2017.1307357<\/a>.<\/p>\n<p>Lemelle, Lauriane, Ga\u00eblle Pierron, Paul Fr\u00e9neaux, Sophie Huybrechts, Alexandra Spiegel, Dominique Plantaz, Morbize Julieron, et al. \u00ab\u00a0NUT Carcinoma in Children and Adults: A Multicenter Retrospective Study\u00a0\u00bb. <em>Pediatric Blood &amp; Cancer<\/em> 64, n<sup>o<\/sup> 12 (d\u00e9cembre 2017). <a href=\"https:\/\/doi.org\/10.1002\/pbc.26693\">https:\/\/doi.org\/10.1002\/pbc.26693<\/a>.<\/p>\n<p>Manier, Salomon, Xavier Leleu, et Herv\u00e9 Avet-Loiseau. \u00ab\u00a0[Circulating exosomal microRNA as biomarkers in mutiple myeloma]\u00a0\u00bb. <em>Medecine Sciences: M\/S<\/em> 33, n<sup>o<\/sup> 11 (novembre 2017): 939\u201141. <a href=\"https:\/\/doi.org\/10.1051\/medsci\/20173311008\">https:\/\/doi.org\/10.1051\/medsci\/20173311008<\/a>.<\/p>\n<p>Millot, Fr\u00e9d\u00e9ric, Christelle Dupraz, Joelle Guilhot, Meinolf Suttorp, Fran\u00e7oise Brizard, Thierry Leblanc, Adalet Meral G\u00fcne\u015f, et al. \u00ab\u00a0Additional Cytogenetic Abnormalities and Variant t(9;22) at the Diagnosis of Childhood Chronic Myeloid Leukemia: The Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents\u00a0\u00bb. <em>Cancer<\/em> 123, n<sup>o<\/sup> 18 (15 septembre 2017): 3609\u201116. <a href=\"https:\/\/doi.org\/10.1002\/cncr.30767\">https:\/\/doi.org\/10.1002\/cncr.30767<\/a>.<\/p>\n<p>Millot, Fr\u00e9d\u00e9ric, Jo\u00eblle Guilhot, Meinolf Suttorp, Adalet Meral G\u00fcne\u015f, Petr Sedlacek, Eveline De Bont, Chi Kong Li, et al. \u00ab\u00a0Prognostic Discrimination Based on the EUTOS Long-Term Survival Score within the International Registry for Chronic Myeloid Leukemia in Children and Adolescents\u00a0\u00bb. <em>Haematologica<\/em> 102, n<sup>o<\/sup> 10 (2017): 1704\u20118. <a href=\"https:\/\/doi.org\/10.3324\/haematol.2017.170035\">https:\/\/doi.org\/10.3324\/haematol.2017.170035<\/a>.<\/p>\n<p>Mondelaers, Veerle, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Fran\u00e7oise Mazingue, Genevi\u00e8ve Plat, Karima Yakouben, et al. \u00ab\u00a0Prolonged versus Standard Native E. Coli Asparaginase Therapy in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: Final Results of the EORTC-CLG Randomized Phase III Trial 58951\u00a0\u00bb. <em>Haematologica<\/em> 102, n<sup>o<\/sup> 10 (2017): 1727\u201138. <a href=\"https:\/\/doi.org\/10.3324\/haematol.2017.165845\">https:\/\/doi.org\/10.3324\/haematol.2017.165845<\/a>.<\/p>\n<p>Piette, C., S. Suciu, E. Clappier, Y. Bertrand, S. Drunat, S. Girard, K. Yakouben, et al. \u00ab\u00a0Differential Impact of Drugs on the Outcome of ETV6-RUNX1 Positive Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia: Results of the EORTC CLG 58881 and 58951 Trials\u00a0\u00bb. <em>Leukemia<\/em> 32, n<sup>o<\/sup> 1 (2018): 244\u201148. <a href=\"https:\/\/doi.org\/10.1038\/leu.2017.289\">https:\/\/doi.org\/10.1038\/leu.2017.289<\/a>.<\/p>\n<p>Poulain, St\u00e9phanie, Christophe Roumier, Elisabeth Bertrand, Aline Renneville, Aur\u00e9lie Caillault-Venet, Emmanuelle Doye, Sandrine Geffroy, et al. \u00ab\u00a0TP53 Mutation and Its Prognostic Significance in Waldenstrom\u2019s Macroglobulinemia\u00a0\u00bb. <em>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research<\/em> 23, n<sup>o<\/sup> 20 (15 octobre 2017): 6325\u201135. <a href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0007\">https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0007<\/a>.<\/p>\n<p>Rea, Delphine, Guylaine Henry, Zena Khaznadar, Gabriel Etienne, Fran\u00e7ois Guilhot, Franck Nicolini, Joelle Guilhot, et al. \u00ab\u00a0Natural Killer-Cell Counts Are Associated with Molecular Relapse-Free Survival after Imatinib Discontinuation in Chronic Myeloid Leukemia: The IMMUNOSTIM Study\u00a0\u00bb. <em>Haematologica<\/em> 102, n<sup>o<\/sup> 8 (2017): 1368\u201177. <a href=\"https:\/\/doi.org\/10.3324\/haematol.2017.165001\">https:\/\/doi.org\/10.3324\/haematol.2017.165001<\/a>.<\/p>\n<p>Rea, Delphine, Franck E. Nicolini, Michel Tulliez, Fran\u00e7ois Guilhot, Joelle Guilhot, Agn\u00e8s Guerci-Bresler, Martine Gardembas, et al. \u00ab\u00a0Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G-TKI Study\u00a0\u00bb. <em>Blood<\/em> 129, n<sup>o<\/sup> 7 (16 2017): 846\u201154. <a href=\"https:\/\/doi.org\/10.1182\/blood-2016-09-742205\">https:\/\/doi.org\/10.1182\/blood-2016-09-742205<\/a>.<\/p>\n<p>Rousselot, Philippe, St\u00e9phane Prost, Joelle Guilhot, Lydia Roy, Gabriel Etienne, Laurence Legros, Aude Charbonnier, et al. \u00ab\u00a0Pioglitazone Together with Imatinib in Chronic Myeloid Leukemia: A Proof of Concept Study\u00a0\u00bb. <em>Cancer<\/em> 123, n<sup>o<\/sup> 10 (15 2017): 1791\u201199. <a href=\"https:\/\/doi.org\/10.1002\/cncr.30490\">https:\/\/doi.org\/10.1002\/cncr.30490<\/a>.<\/p>\n<p>Schorb, E., C. P. Fox, K. Fritsch, L. Isbell, A. Neubauer, A. Tzalavras, R. Witherall, et al. \u00ab\u00a0High-Dose Thiotepa-Based Chemotherapy with Autologous Stem Cell Support in Elderly Patients with Primary Central Nervous System Lymphoma: A European Retrospective Study\u00a0\u00bb. <em>Bone Marrow Transplantation<\/em> 52, n<sup>o<\/sup> 8 (ao\u00fbt 2017): 1113\u201119. <a href=\"https:\/\/doi.org\/10.1038\/bmt.2017.23\">https:\/\/doi.org\/10.1038\/bmt.2017.23<\/a>.<\/p>\n<p>Sch\u00fctz, C., S. Inselmann, S. Saussele, C. T. Dietz, M. C. Mu Ller, E. Eigendorff, C. A. Brendel, et al. \u00ab\u00a0Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (PDC) Predicts Risk of Disease Recurrence after Treatment Discontinuation in CML\u00a0\u00bb. <em>Leukemia<\/em> 31, n<sup>o<\/sup> 4 (2017): 829\u201136. <a href=\"https:\/\/doi.org\/10.1038\/leu.2017.9\">https:\/\/doi.org\/10.1038\/leu.2017.9<\/a>.<\/p>\n<p>Sens, Florence, D\u00e9borah Chaintreuil, Anne Jolivot, Fitsum Guebre-Egziabher, Philip Robinson, Lionel Karlin, Frank Bridoux, et Laurent Juillard. \u00ab\u00a0Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study\u00a0\u00bb. <em>American Journal of Nephrology<\/em> 46, n<sup>o<\/sup> 5 (2017): 355\u201163. <a href=\"https:\/\/doi.org\/10.1159\/000481461\">https:\/\/doi.org\/10.1159\/000481461<\/a>.<\/p>\n<p>Vignon, Marguerite, Camille Cohen, Stanislas Faguer, Laure-H\u00e9l\u00e8ne Noel, Celine Guilbeau, Marion Rabant, Sarah Higgins, et al. \u00ab\u00a0The Clinicopathologic Characteristics of Kidney Diseases Related to Monotypic IgA Deposits\u00a0\u00bb. <em>Kidney International<\/em> 91, n<sup>o<\/sup> 3 (2017): 720\u201128. <a href=\"https:\/\/doi.org\/10.1016\/j.kint.2016.10.026\">https:\/\/doi.org\/10.1016\/j.kint.2016.10.026<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<h3><span style=\"color: #bd3937;\">2016<\/span><\/h3>\n<p>Basbous, Sara, Ana\u00efs Levescot, Nathalie Piccirilli, Fran\u00e7oise Brizard, Fran\u00e7ois Guilhot, Lydia Roy, Nicolas Bourmeyster, Jean-Marc Gombert, et Andr\u00e9 Herbelin. \u00ab\u00a0The Rho-ROCK Pathway as a New Pathological Mechanism of Innate Immune Subversion in Chronic Myeloid Leukaemia\u00a0\u00bb. <em>The Journal of Pathology<\/em> 240, n<sup>o<\/sup> 3 (2016): 262\u201168. <a href=\"https:\/\/doi.org\/10.1002\/path.4779\">https:\/\/doi.org\/10.1002\/path.4779<\/a>.<\/p>\n<p>Boyle, Eileen, Salomon Manier, Julie Lejeune, Guillemette Fouquet, Stephanie Guidez, Sarah Bonnet, Houria Debarri, et al. \u00ab\u00a0IgM\u03ba and IgM\u03bb Measurements for the Assessment of Patients with Waldenstr\u00f6m\u2019s Macroglobulinaemia\u00a0\u00bb. <em>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research<\/em> 22, n<sup>o<\/sup> 20 (15 octobre 2016): 5152\u201158. <a href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2899\">https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2899<\/a>.<\/p>\n<p>Bridoux, Frank, Nianhang Chen, Stephane Moreau, Bertrand Arnulf, Eric Moumas, Julie Abraham, Estelle Desport, Arnaud Jaccard, et Jean Paul Fermand. \u00ab\u00a0Pharmacokinetics, Safety, and Efficacy of Lenalidomide plus Dexamethasone in Patients with Multiple Myeloma and Renal Impairment\u00a0\u00bb. <em>Cancer Chemotherapy and Pharmacology<\/em> 78, n<sup>o<\/sup> 1 (juillet 2016): 173\u201182. <a href=\"https:\/\/doi.org\/10.1007\/s00280-016-3068-9\">https:\/\/doi.org\/10.1007\/s00280-016-3068-9<\/a>.<\/p>\n<p>Cayssials, Emilie, et Francois Guilhot. \u00ab\u00a0Beyond Tyrosine Kinase Inhibitors: Combinations and Other Agents\u00a0\u00bb. <em>Best Practice &amp; Research. Clinical Haematology<\/em> 29, n<sup>o<\/sup> 3 (2016): 271\u201183. <a href=\"https:\/\/doi.org\/10.1016\/j.beha.2016.10.017\">https:\/\/doi.org\/10.1016\/j.beha.2016.10.017<\/a>.<\/p>\n<p>De Veirman, Kim, Jinheng Wang, Song Xu, Xavier Leleu, Eddy Himpe, Ken Maes, Elke De Bruyne, et al. \u00ab\u00a0Induction of MiR-146a by Multiple Myeloma Cells in Mesenchymal Stromal Cells Stimulates Their pro-Tumoral Activity\u00a0\u00bb. <em>Cancer Letters<\/em> 377, n<sup>o<\/sup> 1 (10 2016): 17\u201124. <a href=\"https:\/\/doi.org\/10.1016\/j.canlet.2016.04.024\">https:\/\/doi.org\/10.1016\/j.canlet.2016.04.024<\/a>.<\/p>\n<p>Deininger, Michael W., J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, et al. \u00ab\u00a0Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients\u00a0\u00bb. <em>Blood<\/em> 127, n<sup>o<\/sup> 6 (11 f\u00e9vrier 2016): 703\u201112. <a href=\"https:\/\/doi.org\/10.1182\/blood-2015-08-660977\">https:\/\/doi.org\/10.1182\/blood-2015-08-660977<\/a>.<\/p>\n<p>Dejoie, Thomas, Jill Corre, Helene Caillon, Cyrille Hulin, Aurore Perrot, Denis Caillot, Eileen Boyle, et al. \u00ab\u00a0Serum Free Light Chains, Not Urine Specimens, Should Be Used to Evaluate Response in Light-Chain Multiple Myeloma\u00a0\u00bb. <em>Blood<\/em> 128, n<sup>o<\/sup> 25 (22 2016): 2941\u201148. <a href=\"https:\/\/doi.org\/10.1182\/blood-2016-07-726778\">https:\/\/doi.org\/10.1182\/blood-2016-07-726778<\/a>.<\/p>\n<p>Geyer, Holly L., Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter Aw Te Boekhorst, et al. \u00ab\u00a0Associations between Gender, Disease Features and Symptom Burden in Patients with Myeloproliferative Neoplasms: An Analysis by the MPN QOL International Working Group\u00a0\u00bb. <em>Haematologica<\/em> 102, n<sup>o<\/sup> 1 (2017): 85\u201193. <a href=\"https:\/\/doi.org\/10.3324\/haematol.2016.149559\">https:\/\/doi.org\/10.3324\/haematol.2016.149559<\/a>.<\/p>\n<p>Guilhot, Fran\u00e7ois. \u00ab\u00a0Cytogenetics in CML: More Important than You Think\u00a0\u00bb. <em>Blood<\/em> 127, n<sup>o<\/sup> 22 (02 2016): 2661\u201162. <a href=\"https:\/\/doi.org\/10.1182\/blood-2016-04-708206\">https:\/\/doi.org\/10.1182\/blood-2016-04-708206<\/a>.<\/p>\n<p>Herbaux, Charles, Elisabeth Bertrand, Guillemette Marot, Christophe Roumier, Nicolas Poret, Val\u00e9rie Soenen, Olivier Nibourel, et al. \u00ab\u00a0BACH2 Promotes Indolent Clinical Presentation in Waldenstr\u00f6m Macroglobulinemia\u00a0\u00bb. <em>Oncotarget<\/em> 8, n<sup>o<\/sup> 34 (22 ao\u00fbt 2017): 57451\u201159. <a href=\"https:\/\/doi.org\/10.18632\/oncotarget.9917\">https:\/\/doi.org\/10.18632\/oncotarget.9917<\/a>.<\/p>\n<p>Hulin, Cyrille, Andrew Belch, Chaim Shustik, Maria Teresa Petrucci, Ulrich D\u00fchrsen, Jin Lu, Kevin Song, et al. \u00ab\u00a0Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial\u00a0\u00bb. <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology<\/em> 34, n<sup>o<\/sup> 30 (20 2016): 3609\u201117. <a href=\"https:\/\/doi.org\/10.1200\/JCO.2016.66.7295\">https:\/\/doi.org\/10.1200\/JCO.2016.66.7295<\/a>.<\/p>\n<p>Khoury, Hanna J., Stuart L. Goldberg, Michael J. Mauro, Richard M. Stone, Michael W. Deininger, M. Brigid Bradley-Garelik, Hesham Mohamed, et Fran\u00e7ois Guilhot. \u00ab\u00a0Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia\u00a0\u00bb. <em>Clinical Lymphoma, Myeloma &amp; Leukemia<\/em> 16, n<sup>o<\/sup> 6 (2016): 341-349.e1. <a href=\"https:\/\/doi.org\/10.1016\/j.clml.2016.03.004\">https:\/\/doi.org\/10.1016\/j.clml.2016.03.004<\/a>.<\/p>\n<p>Lipton, Jeffrey H., Charles Chuah, Agn\u00e8s Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, et al. \u00ab\u00a0Ponatinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia: An International, Randomised, Open-Label, Phase 3 Trial\u00a0\u00bb. <em>The Lancet. Oncology<\/em> 17, n<sup>o<\/sup> 5 (2016): 612\u201121. <a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2\">https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2<\/a>.<\/p>\n<p>Padula, William V., Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, et al. \u00ab\u00a0Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States\u00a0\u00bb. <em>Journal of the National Cancer Institute<\/em> 108, n<sup>o<\/sup> 7 (juillet 2016). <a href=\"https:\/\/doi.org\/10.1093\/jnci\/djw003\">https:\/\/doi.org\/10.1093\/jnci\/djw003<\/a>.<\/p>\n<p>Pfirrmann, M., M. Baccarani, S. Saussele, J. Guilhot, F. Cervantes, G. Ossenkoppele, V. S. Hoffmann, et al. \u00ab\u00a0Prognosis of Long-Term Survival Considering Disease-Specific Death in Patients with Chronic Myeloid Leukemia\u00a0\u00bb. <em>Leukemia<\/em> 30, n<sup>o<\/sup> 1 (janvier 2016): 48\u201156. <a href=\"https:\/\/doi.org\/10.1038\/leu.2015.261\">https:\/\/doi.org\/10.1038\/leu.2015.261<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<h3><span style=\"color: #bd3937;\">2015<\/span><\/h3>\n<p>PubMed. \u00ab\u00a025196702 25346428 25435115 25573033 25783795 25903796 26050650 26118501 26474455 26484337 26511135 26603508 26688235 &#8211; Search Results\u00a0\u00bb. Consult\u00e9 le 25 juin 2020. <a href=\"https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/?term=25196702+25346428+25435115+25573033+25783795+25903796+26050650+26118501+26474455+26484337+26511135+26603508+26688235\">https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/?term=25196702+25346428+25435115+25573033+25783795+25903796+26050650+26118501+26474455+26484337+26511135+26603508+26688235<\/a>.<\/p>\n<p>Aladjidi, Nathalie, Helder Fernandes, Thierry Leblanc, Am\u00e9lie Vareliette, Fr\u00e9d\u00e9ric Rieux-Laucat, Yves Bertrand, Herv\u00e9 Chambost, et al. \u00ab\u00a0Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort\u00a0\u00bb. <em>Frontiers in Pediatrics<\/em> 3 (2015): 79. <a href=\"https:\/\/doi.org\/10.3389\/fped.2015.00079\">https:\/\/doi.org\/10.3389\/fped.2015.00079<\/a>.<\/p>\n<p>Br\u00fcmmendorf, Tim H., Jorge E. Cortes, C\u00e1rmino Antonio de Souza, Francois Guilhot, Ladan Duvilli\u00e9, Dmitri Pavlov, Kar\u00efn Gogat, Athena M. Countouriotis, et Carlo Gambacorti-Passerini. \u00ab\u00a0Bosutinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia: Results from the 24-Month Follow-up of the BELA Trial\u00a0\u00bb. <em>British Journal of Haematology<\/em> 168, n<sup>o<\/sup> 1 (janvier 2015): 69\u201181. <a href=\"https:\/\/doi.org\/10.1111\/bjh.13108\">https:\/\/doi.org\/10.1111\/bjh.13108<\/a>.<\/p>\n<p>Bruzzoni-Giovanelli, Heriberto, Juan R. Gonz\u00e1lez, Fran\u00e7ois Sigaux, Bruno O. Villoutreix, Jean Michel Cayuela, Jo\u00eblle Guilhot, Claude Preudhomme, Fran\u00e7ois Guilhot, Jean-Luc Poyet, et Philippe Rousselot. \u00ab\u00a0Genetic Polymorphisms Associated with Increased Risk of Developing Chronic Myelogenous Leukemia\u00a0\u00bb. <em>Oncotarget<\/em> 6, n<sup>o<\/sup> 34 (3 novembre 2015): 36269\u201177. <a href=\"https:\/\/doi.org\/10.18632\/oncotarget.5915\">https:\/\/doi.org\/10.18632\/oncotarget.5915<\/a>.<\/p>\n<p>Clappier, E., N. Grardel, M. Bakkus, J. Rapion, B. De Moerloose, P. Kastner, A. Caye, et al. \u00ab\u00a0IKZF1 Deletion Is an Independent Prognostic Marker in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia, and Distinguishes Patients Benefiting from Pulses during Maintenance Therapy: Results of the EORTC Children\u2019s Leukemia Group Study 58951\u00a0\u00bb. <em>Leukemia<\/em> 29, n<sup>o<\/sup> 11 (novembre 2015): 2154\u201161. <a href=\"https:\/\/doi.org\/10.1038\/leu.2015.134\">https:\/\/doi.org\/10.1038\/leu.2015.134<\/a>.<\/p>\n<p>Dkhissi, Fatima, Djamel Aggoune, Julien Pontis, Nathalie Sorel, Nathalie Piccirilli, Am\u00e9lie LeCorf, Fran\u00e7ois Guilhot, Jean-Claude Chomel, Slimane Ait-Si-Ali, et Ali G. Turhan. \u00ab\u00a0The Downregulation of BAP1 Expression by BCR-ABL Reduces the Stability of BRCA1 in Chronic Myeloid Leukemia\u00a0\u00bb. <em>Experimental Hematology<\/em> 43, n<sup>o<\/sup> 9 (septembre 2015): 775\u201180. <a href=\"https:\/\/doi.org\/10.1016\/j.exphem.2015.04.013\">https:\/\/doi.org\/10.1016\/j.exphem.2015.04.013<\/a>.<\/p>\n<p>Guilhot, Jo\u00eblle, Claude Preudhomme, Francois Xavier Mahon, et Fran\u00e7ois Guilhot. \u00ab\u00a0Analyzing Molecular Response in Chronic Myeloid Leukemia Clinical Trials: Pitfalls and Golden Rules\u00a0\u00bb. <em>Cancer<\/em> 121, n<sup>o<\/sup> 4 (15 f\u00e9vrier 2015): 490\u201197. <a href=\"https:\/\/doi.org\/10.1002\/cncr.29053\">https:\/\/doi.org\/10.1002\/cncr.29053<\/a>.<\/p>\n<p>Hijiya, Nobuko, Frederic Millot, et Meinolf Suttorp. \u00ab\u00a0Chronic Myeloid Leukemia in Children: Clinical Findings, Management, and Unanswered Questions\u00a0\u00bb. <em>Pediatric Clinics of North America<\/em> 62, n<sup>o<\/sup> 1 (f\u00e9vrier 2015): 107\u201119. <a href=\"https:\/\/doi.org\/10.1016\/j.pcl.2014.09.008\">https:\/\/doi.org\/10.1016\/j.pcl.2014.09.008<\/a>.<\/p>\n<p>Hijiya, Nobuko, Kirk R. Schultz, Markus Metzler, Frederic Millot, et Meinolf Suttorp. \u00ab\u00a0Pediatric Chronic Myeloid Leukemia Is a Unique Disease That Requires a Different Approach\u00a0\u00bb. <em>Blood<\/em> 127, n<sup>o<\/sup> 4 (28 janvier 2016): 392\u201199. <a href=\"https:\/\/doi.org\/10.1182\/blood-2015-06-648667\">https:\/\/doi.org\/10.1182\/blood-2015-06-648667<\/a>.<\/p>\n<p>Hoffmann, V. S., M. Baccarani, J. Hasford, D. Lindoerfer, S. Burgstaller, D. Sertic, P. Costeas, et al. \u00ab\u00a0The EUTOS Population-Based Registry: Incidence and Clinical Characteristics of 2904 CML Patients in 20 European Countries\u00a0\u00bb. <em>Leukemia<\/em> 29, n<sup>o<\/sup> 6 (juin 2015): 1336\u201143. <a href=\"https:\/\/doi.org\/10.1038\/leu.2015.73\">https:\/\/doi.org\/10.1038\/leu.2015.73<\/a>.<\/p>\n<p>Jacomet, Florence, Emilie Cayssials, Sara Basbous, Ana\u00efs Levescot, Nathalie Piccirilli, Deborah Desmier, Aur\u00e9lie Robin, et al. \u00ab\u00a0Evidence for Eomesodermin-Expressing Innate-like CD8(+) KIR\/NKG2A(+) T\u00a0Cells in Human Adults and Cord Blood Samples\u00a0\u00bb. <em>European Journal of Immunology<\/em> 45, n<sup>o<\/sup> 7 (juillet 2015): 1926\u201133. <a href=\"https:\/\/doi.org\/10.1002\/eji.201545539\">https:\/\/doi.org\/10.1002\/eji.201545539<\/a>.<\/p>\n<p>Millot, Fr\u00e9d\u00e9ric, et Meinolf Suttorp. \u00ab\u00a0Managing Children with Chronic Myeloid Leukaemia&#8211;Response to Baccarani\u00a0\u00bb. <em>British Journal of Haematology<\/em> 169, n<sup>o<\/sup> 5 (juin 2015): 760\u201161. <a href=\"https:\/\/doi.org\/10.1111\/bjh.13249\">https:\/\/doi.org\/10.1111\/bjh.13249<\/a>.<\/p>\n<p>Omuro, Antonio, Olivier Chinot, Luc Taillandier, Herv\u00e9 Ghesquieres, Carole Soussain, Vincent Delwail, Thierry Lamy, et al. \u00ab\u00a0Methotrexate and Temozolomide versus Methotrexate, Procarbazine, Vincristine, and Cytarabine for Primary CNS Lymphoma in an Elderly Population: An Intergroup ANOCEF-GOELAMS Randomised Phase 2 Trial\u00a0\u00bb. <em>The Lancet. Haematology<\/em> 2, n<sup>o<\/sup> 6 (juin 2015): e251-259. <a href=\"https:\/\/doi.org\/10.1016\/S2352-3026(15)00074-5\">https:\/\/doi.org\/10.1016\/S2352-3026(15)00074-5<\/a>.<\/p>\n<p>Puyade, M., G. Defossez, F. Guilhot, et P. Ingrand. \u00ab\u00a0Multiple Myeloma: The Quality of Care Is Linked to Geographical and Organisational Determinants. A Study in a French Registry\u00a0\u00bb. <em>European Journal of Cancer Care<\/em> 25, n<sup>o<\/sup> 5 (septembre 2016): 855\u201163. <a href=\"https:\/\/doi.org\/10.1111\/ecc.12414\">https:\/\/doi.org\/10.1111\/ecc.12414<\/a>.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbLiens &#8211; Partenariats\u00a0\u00bb tab_id=\u00a0\u00bb1662550733837-757fd338-7a0c\u00a0\u00bb][vc_column_text]\n<ul>\n<li><a title=\"\" href=\"http:\/\/www.hematology.org\/\">American Society of Hematology<\/a><\/li>\n<li><a title=\"\" href=\"http:\/\/ehaweb.org\/\">European Society of Hematology<\/a><\/li>\n<li><a title=\"\" href=\"http:\/\/sfh.hematologie.net\/pages\/?all=accueil\">Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019H\u00e9matologie<\/a><\/li>\n<li><a title=\"\" href=\"http:\/\/www.leukemia-net.org\/content\/home\/index_eng.html\">European Leukemia net<\/a><\/li>\n<li><a title=\"\" href=\"http:\/\/www.lmc-cml.org\/fr\/\">France Intergroupe de la Leuc\u00e9mie My\u00e9lo\u00efde Chronique<\/a><\/li>\n<\/ul>\n[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbContact\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:mailto%3Axavier.leleu%40chu-poitiers.fr||target:%20_blank|\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbVoir le poster\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fcentre-dinvestigation-clinique%2Fwp-content%2Fuploads%2Fsites%2F71%2F2020%2F07%2Fposter-THOR-juillet-2020.jpg||target:%20_blank|\u00a0\u00bb][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_custom_heading text=\u00a0\u00bbTarget in Hematology and Oncology Research\u00a0\u00bb font_container=\u00a0\u00bbtag:h2|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb755&Prime;][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb349&Prime; alignment=\u00a0\u00bbcenter\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb1111&Prime;][\/vc_column][\/vc_row][vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1595343295102{margin-right: 20px !important;}\u00a0\u00bb][vc_column_text]Canc\u00e9rologie p\u00e9diatrique, canc\u00e9rologie adulte (oncologie m\u00e9dicale, h\u00e9matologie oncologie, cancer et rein), registre des cancers [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=\u00a0\u00bb162&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_accordion style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb12&Prime; no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbVue d&rsquo;ensemble\u00a0\u00bb tab_id=\u00a0\u00bb1614697670792-e384d485-408a\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb.vc_custom_1595343317315{padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-147","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Axe Thor - Centre d&#039;investigation clinique (CIC 1402)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axe Thor - Centre d&#039;investigation clinique (CIC 1402)\" \/>\n<meta property=\"og:description\" content=\"[vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_custom_heading text=\u00a0\u00bbTarget in Hematology and Oncology Research\u00a0\u00bb font_container=\u00a0\u00bbtag:h2|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb755&Prime;][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb349&Prime; alignment=\u00a0\u00bbcenter\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb1111&Prime;][\/vc_column][\/vc_row][vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1595343295102{margin-right: 20px !important;}\u00a0\u00bb][vc_column_text]Canc\u00e9rologie p\u00e9diatrique, canc\u00e9rologie adulte (oncologie m\u00e9dicale, h\u00e9matologie oncologie, cancer et rein), registre des cancers [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=\u00a0\u00bb162&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_accordion style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb12&Prime; no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbVue d&rsquo;ensemble\u00a0\u00bb tab_id=\u00a0\u00bb1614697670792-e384d485-408a\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb.vc_custom_1595343317315{padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/\" \/>\n<meta property=\"og:site_name\" content=\"Centre d&#039;investigation clinique (CIC 1402)\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T09:31:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"30 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/axe-thor\\\/\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/axe-thor\\\/\",\"name\":\"Axe Thor - Centre d&#039;investigation clinique (CIC 1402)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/#website\"},\"datePublished\":\"2020-07-21T14:42:36+00:00\",\"dateModified\":\"2026-07-16T09:31:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/axe-thor\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/axe-thor\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/axe-thor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"CHU de Poitiers\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Services\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/services\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Centre d&#039;investigation clinique (CIC 1402)\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Axe Thor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/#website\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/\",\"name\":\"Centre d&#039;investigation clinique (CIC 1402)\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/centre-dinvestigation-clinique\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axe Thor - Centre d&#039;investigation clinique (CIC 1402)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/","og_locale":"fr_FR","og_type":"article","og_title":"Axe Thor - Centre d&#039;investigation clinique (CIC 1402)","og_description":"[vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2&Prime;][vc_custom_heading text=\u00a0\u00bbTarget in Hematology and Oncology Research\u00a0\u00bb font_container=\u00a0\u00bbtag:h2|text_align:left|color:%23bd3937&Prime; use_theme_fonts=\u00a0\u00bbyes\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb755&Prime;][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb349&Prime; alignment=\u00a0\u00bbcenter\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb1\/6&Prime;][vc_single_image image=\u00a0\u00bb1111&Prime;][\/vc_column][\/vc_row][vc_row content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1595343295102{margin-right: 20px !important;}\u00a0\u00bb][vc_column_text]Canc\u00e9rologie p\u00e9diatrique, canc\u00e9rologie adulte (oncologie m\u00e9dicale, h\u00e9matologie oncologie, cancer et rein), registre des cancers [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=\u00a0\u00bb162&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_accordion style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb12&Prime; no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbVue d&rsquo;ensemble\u00a0\u00bb tab_id=\u00a0\u00bb1614697670792-e384d485-408a\u00a0\u00bb][vc_row_inner content_placement=\u00a0\u00bbmiddle\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_column_text css=\u00a0\u00bb.vc_custom_1595343317315{padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: [&hellip;]","og_url":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/","og_site_name":"Centre d&#039;investigation clinique (CIC 1402)","article_modified_time":"2026-07-16T09:31:43+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"30 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/","url":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/","name":"Axe Thor - Centre d&#039;investigation clinique (CIC 1402)","isPartOf":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/#website"},"datePublished":"2020-07-21T14:42:36+00:00","dateModified":"2026-07-16T09:31:43+00:00","breadcrumb":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/axe-thor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"CHU de Poitiers","item":"https:\/\/www.chu-poitiers.fr\/"},{"@type":"ListItem","position":2,"name":"Services","item":"https:\/\/www.chu-poitiers.fr\/services\/"},{"@type":"ListItem","position":3,"name":"Centre d&#039;investigation clinique (CIC 1402)","item":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/"},{"@type":"ListItem","position":4,"name":"Axe Thor"}]},{"@type":"WebSite","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/#website","url":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/","name":"Centre d&#039;investigation clinique (CIC 1402)","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/pages\/147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/comments?post=147"}],"version-history":[{"count":5,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/pages\/147\/revisions"}],"predecessor-version":[{"id":2069,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/pages\/147\/revisions\/2069"}],"wp:attachment":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/centre-dinvestigation-clinique\/wp-json\/wp\/v2\/media?parent=147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}